<bill session="109" type="h" number="3154" updated="2023-01-13T04:47:49Z">
  <state datetime="2005-06-30">REFERRED</state>
  <status>
    <introduced datetime="2005-06-30"/>
  </status>
  <introduced datetime="2005-06-30"/>
  <titles>
    <title type="display">Infectious Diseases Research and Development Act of 2005</title>
    <title type="official" as="introduced">To provide incentives for pharmaceutical companies, biotechnology companies, and medical device companies to invest in research and development with respect to antibiotic drugs, antivirals, diagnostic tests, and vaccines that may be used to identify, treat, or prevent an infectious disease, and for other purposes.</title>
    <title type="short" as="introduced">Infectious Diseases Research and Development Act of 2005</title>
  </titles>
  <sponsor bioguide_id="C000962"/>
  <cosponsors>
    <cosponsor bioguide_id="B001229" joined="2005-06-30"/>
    <cosponsor bioguide_id="B000072" joined="2005-06-30"/>
    <cosponsor bioguide_id="B001244" joined="2005-06-30"/>
    <cosponsor bioguide_id="D000602" joined="2005-06-30" withdrawn="2005-07-18"/>
    <cosponsor bioguide_id="G000550" joined="2005-06-30"/>
    <cosponsor bioguide_id="L000552" joined="2005-06-30"/>
    <cosponsor bioguide_id="M001142" joined="2005-06-30"/>
    <cosponsor bioguide_id="W000267" joined="2005-06-30"/>
  </cosponsors>
  <actions>
    <action datetime="2005-06-30">
      <text>Introduced in House</text>
    </action>
    <action datetime="2005-06-30" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2005-06-30">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2005-06-30">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2005-07-29">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
    <committee code="HSJU" name="House Judiciary" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative procedure"/>
    <term name="Administrative remedies"/>
    <term name="Antibiotics"/>
    <term name="Authorization"/>
    <term name="Bacterial diseases"/>
    <term name="Building construction"/>
    <term name="Capital investments"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Communicable diseases"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Department of Health and Human Services"/>
    <term name="District courts"/>
    <term name="Drug approvals"/>
    <term name="Drug industry"/>
    <term name="Drug resistance in microorganisms"/>
    <term name="Economics and Public Finance"/>
    <term name="Epidemics"/>
    <term name="Federal advisory bodies"/>
    <term name="Federal aid to research"/>
    <term name="Finance and Financial Sector"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government Operations and Politics"/>
    <term name="Government paperwork"/>
    <term name="Income tax"/>
    <term name="Influenza"/>
    <term name="Intellectual property"/>
    <term name="Inventions"/>
    <term name="Investment tax credit"/>
    <term name="Jurisdiction"/>
    <term name="Laboratories"/>
    <term name="Law"/>
    <term name="Lung diseases"/>
    <term name="Medical supplies"/>
    <term name="Medical technology"/>
    <term name="Medical tests"/>
    <term name="Patents"/>
    <term name="Pharmaceutical research"/>
    <term name="Product development"/>
    <term name="Products liability"/>
    <term name="Punitive damages"/>
    <term name="Research and development"/>
    <term name="Research and development facilities"/>
    <term name="Research grants"/>
    <term name="Science, Technology, Communications"/>
    <term name="Small business"/>
    <term name="Standards"/>
    <term name="Subsidies"/>
    <term name="Tax credits"/>
    <term name="Tax deductions"/>
    <term name="Taxation"/>
    <term name="Vaccines"/>
    <term name="Virus diseases"/>
  </subjects>
  <amendments/>
  <summary date="2005-09-21T20:18:31Z" status="Introduced in House">Infectious Diseases Research and Development Act of 2005 - Limits the liability of manufacturers of qualified infectious disease products by limiting: (1) punitive damages unless the manufacturer acted with malicious intent to injure the individual or deliberately failed to avoid unnecessary injury that the manufacturer knew the individual was substantially certain to suffer; and (2) non-economic damages to $250,000.

Sets forth circumstances under which the term of a patent may be extended for qualified infectious disease products.

Requires the Secretary of Health and Human Services to designate qualified infectious disease products as fast-track products for approval.

Amends the Public Health Service Act to require the Director of the National Institute of Allergy and Infectious Diseases to expand and intensify efforts to assist small manufacturers to conduct end-stage clinical trials on qualified infectious disease products.

Amends the Internal Revenue Code to establish an infectious disease research credit and a qualified infectious disease products manufacturing facilities investment credit.

Authorizes appropriations for activities related to antimicrobial resistance.

Establishes the Commission on Infectious Diseases Product Development to identify infectious pathogens that are a significant threat to public health and make recommendations to the Secretary on how best to address such pathogens.

Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary, acting through the Commissioner of Food and Drugs, to issue guidelines for the conduct of clinical trials with respect to antibiotic drugs.</summary>
</bill>
